The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model

Pouwer, M.G.; Pieterman, E.J.; Verschuren, L.; Caspers, M.P.M.; Kluft, C.; Garcia, R.A.; ... ; Princen, H.M.G. (2018)

Article / Letter to editor

• atherosclerosis
• animal model cardiovascular disease
• lipids and lipoprotein metabolism
• coagulation/thrombosis
• cholesterol
• chronic myeloid leukemia
• cardiovascular side effects

• All authors: Pouwer, M.G.; Pieterman, E.J.; Verschuren, L.; Caspers, M.P.M.; Kluft, C.; Garcia, R.A.; Aman, J.; Jukema, J.W.; Princen, H.M.G.
• Date: 2018-06-12
• Journal: Frontiers in Cardiovascular Medicine
• Volume: 5
• DOI: doi:10.3389/fcvm.2018.00055
• Link: https://www.frontiersin.org/articles/10.3389/fcvm.2018.00055/full